This is a working overview of clinical evidence, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-19. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Origin of replication: Necessary for the replication and maintenance of the vector in the host cell. Promoter: Promoters are used to drive the transcription of the vector's transgene as well as the other genes in the vector such as the antibiotic resistance gene. Some cloning vectors need not have a promoter for the cloned insert but it is an essential component of expression vectors so that the cloned product may be expressed. Cloning site: This may be a multiple cloning site or other features that allow for the insertion of foreign DNA into the vector through ligation. Genetic markers: Genetic markers for viral vectors allow for confirmation that the vector has integrated with the host genomic DNA. Antibiotic resistance: Vectors with antibiotic-resistance open reading frames allow for survival of cells that have taken up the vector in growth media containing antibiotics through antibiotic selection. Epitope: Some vectors may contain a sequence for a specific epitope that can be incorporated into the expressed protein. It allows for antibody identification of cells expressing the target protein. Reporter genes: Some vectors may contain a reporter gene that allow for identification of plasmid that contains inserted DNA sequence. An example is lacZ-α which codes for the N-terminus fragment of β-galactosidase, an enzyme that digests galactose. A multiple cloning site is located within lacZ-α, and an insert successfully ligated into the vector will disrupt the gene sequence, resulting in an inactive β-galactosidase.
=== Glucagon === Glucagon is a hormone that rapidly counters the metabolic effects of insulin in the liver, causing glycogenolysis and release of glucose into the blood. It can raise the glucose by 30–100 mg/dL within minutes in any form of hypoglycemia caused by insulin excess (including all types of diabetic hypoglycemia). It comes in a glucagon emergency rescue kit which includes tiny vials containing 1 mg, which is a standard adult dose. The glucagon in the vial is a lyophilized pellet, which must be reconstituted with 1 mL of sterile water, included in the "kit". In the widely used Lilly Emergency Kit, the water is contained in a syringe with a large needle for intramuscular injection and must be injected into the vial with the pellet of glucagon before being injected. Glucagon works if given subcutaneously, but absorption and recovery are faster if it is injected deep into a muscle (usually the middle of the outside of the thigh). It has an even more rapid effect when given intravenously but this is rarely practicable. Side effects of glucagon can include nausea and headache, but these can also occur after severe hypoglycemia even when glucagon is not used. Risks of glucagon use are far lower than risks of severe hypoglycemia, and it can usually produce a faster recovery than calling for paramedics and waiting for them to start an intravenous line to give dextrose. If someone uses this kit, they should be seen in an emergency room, as glucagon depletes glycogen stores, and can lead to a deadly rebound hypoglycemia.
=== EC 1.2.1 With NAD+ or NADP+ as acceptor === EC 1.2.1.1: deleted, replaced by EC 1.1.1.284, S-(hydroxymethyl)glutathione dehydrogenase and EC 4.4.1.22, S-(hydroxymethyl)glutathione synthase EC 1.2.1.2: Now EC 1.17.1.9, formate dehydrogenase EC 1.2.1.3: aldehyde dehydrogenase (NAD+) EC 1.2.1.4: aldehyde dehydrogenase (NADP+) EC 1.2.1.5: aldehyde dehydrogenase (NAD(P)+) EC 1.2.1.6: deleted (was benzaldehyde dehydrogenase) EC 1.2.1.7: benzaldehyde dehydrogenase (NADP+) EC 1.2.1.8: betaine-aldehyde dehydrogenase EC 1.2.1.9: glyceraldehyde-3-phosphate dehydrogenase (NADP+) EC 1.2.1.10: acetaldehyde dehydrogenase (acetylating) EC 1.2.1.11: aspartate-semialdehyde dehydrogenase EC 1.2.1.12: glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) EC 1.2.1.13: glyceraldehyde-3-phosphate dehydrogenase (NADP+) (phosphorylating) EC 1.2.1.14: Now EC 1.1.1.205, IMP dehydrogenase EC 1.2.1.15: malonate-semialdehyde dehydrogenase EC 1.2.1.16: succinate-semialdehyde dehydrogenase [NAD(P)+] EC 1.2.1.17: glyoxylate dehydrogenase (acylating) EC 1.2.1.18: malonate-semialdehyde dehydrogenase (acetylating) EC 1.2.1.19: aminobutyraldehyde dehydrogenase EC 1.2.1.20: glutarate-semialdehyde dehydrogenase EC 1.2.1.21: glycolaldehyde dehydrogenase EC 1.2.1.22: lactaldehyde dehydrogenase EC 1.2.1.23: 2-oxoaldehyde dehydrogenase (NAD+) EC 1.2.1.24: succinate-semialdehyde dehydrogenase (NAD+) EC 1.2.1.25: branched-chain α-keto acid dehydrogenase system EC 1.2.1.26: 2,5-dioxovalerate dehydrogenase EC 1.2.1.27: methylmalonate-semialdehyde dehydrogenase (CoA-acylating) EC 1.2.1.28: benzaldehyde dehydrogenase (NAD+) EC 1.2.1.29: aryl-aldehyde dehydrogenase EC 1.2.1.30: aryl-aldehyde dehydrogenase (NADP+) EC 1.2.1.31: L-aminoadipate-semialdehyde dehydrogenase EC 1.2.1.32: aminomuconate-semialdehyde dehydrogenase EC 1.2.1.33: (R)-dehydropantoate dehydrogenase EC 1.2.1.34: Now EC 1.1.1.131, mannuronate reductase EC 1.2.1.35: Now EC 1.1.1.203, uronate dehydrogenase EC 1.2.1.36: retinal dehydrogenase EC 1.2.1.37: Now EC 1.17.1.4, xanthine dehydrogenase EC 1.2.1.38: N-acetyl-γ-glutamyl-phosphate reductase EC 1.2.1.39: phenylacetaldehyde dehydrogenase EC 1.2.1.40: part of EC 1.14.13.15, cholestanetriol 26-monooxygenase EC 1.2.1.41: glutamate-5-semialdehyde dehydrogenase EC 1.2.1.42: hexadecanal dehydrogenase (acylating) EC 1.2.1.43: Now EC 1.17.1.10, formate dehydrogenase (NADP+) EC 1.2.1.44: cinnamoyl-CoA reductase EC 1.2.1.45: Now EC 1.1.1.312, 2-hydroxy-4-carboxymuconate semialdehyde hemiacetal dehydrogenase EC 1.2.1.46: formaldehyde dehydrogenase EC 1.2.1.47: 4-trimethylammoniobutyraldehyde dehydrogenase EC 1.2.1.48: long-chain-aldehyde dehydrogenase EC 1.2.1.49: 2-oxoaldehyde dehydrogenase (NADP+) EC 1.2.1.50: long-chain-fatty-acyl-CoA reductase EC 1.2.1.51: pyruvate dehydrogenase (NADP+) EC 1.2.1.52: deleted 2025 (was oxoglutarate dehydrogenase (NADP+)) EC 1.2.1.53: 4-hydroxyphenylacetaldehyde dehydrogenase EC 1.2.1.54: γ-guanidinobutyraldehyde dehydrogenase EC 1.2.1.55: Now EC 1.1.1.279, (R)-3-hydroxyacid-ester dehydrogenase EC 1.2.1.56: Now EC 1.1.1.280, (S)-3-hydroxyacid-ester dehydrogenase EC 1.2.1.57: butanal dehydrogenase EC 1.2.1.58: phenylglyoxylate dehydrogenase (acylating) EC 1.2.1.59: glyceraldehyde-3-phosphate dehydrogenase (NAD(P)+) EC 1.2.1.60: 5-carboxymethyl-2-hydroxymuconic-semialdehyde dehydrogenase EC 1.2.1.61: 4-hydroxymuconic-semialdehyde dehydrogenase EC 1.2.1.62: 4-formylbenzenesulfonate dehydrogenase EC 1.2.1.63: 6-oxohexanoate dehydrogenase EC 1.2.1.64: 4-hydroxybenzaldehyde dehydrogenase (NAD+) EC 1.2.1.65: salicylaldehyde dehydrogenase EC 1.2.1.66: Now EC 1.1.1.306, S-(hydroxymethyl)mycothiol dehydrogenase EC 1.2.1.67: vanillin dehydrogenase EC 1.2.1.68: coniferyl-aldehyde dehydrogenase EC 1.2.1.69: fluoroacetaldehyde dehydrogenase EC 1.2.1.70: glutamyl-tRNA reductase EC 1.2.1.71: succinylglutamate-semialdehyde dehydrogenase EC 1.2.1.72: erythrose-4-phosphate dehydrogenase EC 1.2.1.73: sulfoacetaldehyde dehydrogenase EC 1.2.1.74: abieta-7,13-dien-18-al dehydrogenase EC 1.2.1.75: malonyl CoA reductase (malonate semialdehyde-forming) EC 1.2.1.76: succinate-semialdehyde dehydrogenase (acylating) EC 1.2.1.77: 3,4-dehydroadipyl-CoA semialdehyde dehydrogenase (NADP+) EC 1.2.1.78: 2-formylbenzoate dehydrogenase EC 1.2.1.79: succinate-semialdehyde dehydrogenase (NADP+) EC 1.2.1.80: long-chain acyl-[acyl-carrier-protein] reductase EC 1.2.1.81: sulfoacetaldehyde dehydrogenase (acylating) EC 1.2.1.82: β-apo-4′-carotenal oxygenase EC 1.2.1.83: 3-succinoylsemialdehyde-pyridine dehydrogenase EC 1.2.1.84: alcohol-forming fatty acyl-CoA reductase EC 1.2.1.85: 2-hydroxymuconate-6-semialdehyde dehydrogenase EC 1.2.1.86: geranial dehydrogenase EC 1.2.1.87: propanal dehydrogenase (CoA-propanoylating) EC 1.2.1.88: L-glutamate γ-semialdehyde dehydrogenase EC 1.2.1.89: D-glyceraldehyde dehydrogenase (NADP+) EC 1.2.1.90: glyceraldehyde-3-phosphate dehydrogenase [NAD(P)+] EC 1.2.1.91: 3-oxo-5,6-dehydrosuberyl-CoA semialdehyde dehydrogenase EC 1.2.1.92: 3,6-anhydro-α-L-galactose dehydrogenase EC 1.2.1.93: formate dehydrogenase (NAD+, ferredoxin). Now EC 1.17.1.11, formate dehydrogenase (NAD+, ferredoxin) * EC 1.2.1.94: farnesal dehydrogenase EC 1.2.1.95: L-2-aminoadipate reductase EC 1.2.1.96: 4-hydroxybenzaldehyde dehydrogenase (++) EC 1.2.1.97: 3-sulfolactaldehyde dehydrogenase EC 1.2.1.98: 2-hydroxy-2-methylpropanal dehydrogenase EC 1.2.1.99: 4-(γ-glutamylamino)butanal dehydrogenase EC 1.2.1.100: 5-formyl-3-hydroxy-2-methylpyridine 4-carboxylic acid 5-dehydrogenase EC 1.2.1.101: L-tyrosine reductase EC 1.2.1.102: isopyridoxal dehydrogenase (5-pyridoxate-forming) EC 1.2.1.103: [amino-group carrier protein]-6-phospho-L-2-aminoadipate reductase EC 1.2.1.104: pyruvate dehydrogenase system EC 1.2.1.105: 2-oxoglutarate dehydrogenase system EC 1.2.1.106: [amino-group carrier protein]-5-phospho-L-glutamate reductase EC 1.2.1.107: glyceraldehyde-3-phosphate dehydrogenase (arsenate-transferring)
Sources: en.wikipedia.org
hydrophobic Sometimes used interchangeably with lipophilic. Having a low solubility in or affinity for water or other polar solvents; describing a non-polar molecule, or a moiety or functional group within a molecule, which cannot form energetically favorable interactions with polar compounds and which therefore tends to "avoid" or be repulsed by such compounds, instead clustering together with other hydrophobic molecules or arranging itself in a way that minimizes its exposure to its polar surroundings. This phenomenon is not so much due to the affinity of the hydrophobic molecules for each other as it is a consequence of the strong intermolecular forces that allow polar compounds such as water molecules to bond with each other; hydrophobic species are unable to form alternative bonds of equivalent strength with the polar compounds, hence they tend to be excluded from aqueous solutions by the tendency of the polar solvent to maximize interactions with itself. Hydrophobicity is a major determinant of countless chemical interactions in biological systems, including the spatial conformations assumed by macromolecules such as proteins and lipids, the binding of ligands and substrates to proteins, and the structure and properties of lipid membranes. Contrast hydrophilic.
troops fighting in Vietnam "remains one of our few bargaining weapons". In the same memo, Kissinger stated he was "deeply disturbed" that Nixon had started pulling out U.S. troops, saying that withdrawing the troops was like "salted peanuts" to the American people ("The more U.S troops come home, the more will be demanded"), giving the advantage to the enemy who merely had to "wait us out". Instead, he recommenced that the United States resume bombing North Vietnam and mine the coast. Later in September 1969, Kissinger proposed a plan for what he called a "savage, punishing" blow against North Vietnam code-named Duck Hook to Nixon, arguing that this was the best way to force North Vietnam to agree to peace on American terms. Laird was strongly opposed to Duck Hook, warning Nixon that the use of nuclear weapons to kill a massive number of North Vietnamese civilians would alienate American public opinion from the administration and persuaded Nixon to reject it. Reflecting his background as a Harvard professor of political science who belonged to the Primat der Aussenpolitik school, which saw foreign policy as belonging only to a small elite, Kissinger was less sensitive to public opinion than Laird, a former Republican congressman who constantly advised Nixon to keep American public opinion in mind. Laird used the National Moratorium protests of 15 November 1969 to persuade Nixon to cancel Duck Hook, arguing that if the war as it was had caused the largest demonstrations ever in American history, then Kissinger's plans for Duck Hook would alienate the public even more.
=== Automated === On board the analyzer, the sample is agitated to evenly distribute the cells, then diluted and partitioned into at least two channels, one of which is used to count red blood cells and platelets, the other to count white blood cells and determine the hemoglobin concentration. Some instruments measure hemoglobin in a separate channel, and additional channels may be used for differential white blood cell counts, reticulocyte counts and specialized measurements of platelets. The cells are suspended in a fluid stream and their properties are measured as they flow past sensors in a technique known as flow cytometry. Hydrodynamic focusing may be used to isolate individual cells so that more accurate results can be obtained: the diluted sample is injected into a stream of low-pressure fluid, which causes the cells in the sample to line up in single file through laminar flow.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.